Search alternatives:
2016 decrease » 026 decrease (Expand Search)
ae decrease » we decrease (Expand Search), a decreased (Expand Search), nn decrease (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
_ 2016 » _ 2019 (Expand Search), _ 2015 (Expand Search), _ 2010 (Expand Search)
i ae » i a (Expand Search), i e (Expand Search), i de (Expand Search)
2016 decrease » 026 decrease (Expand Search)
ae decrease » we decrease (Expand Search), a decreased (Expand Search), nn decrease (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
_ 2016 » _ 2019 (Expand Search), _ 2015 (Expand Search), _ 2010 (Expand Search)
i ae » i a (Expand Search), i e (Expand Search), i de (Expand Search)
-
1
-
2
Percentage of <i>Ae. aegypti</i> and <i>Ae. albopictus</i> trapped in each pagoda (pagodas are ordered by a decreasing percentage of <i>Ae. aegypti</i>).
Published 2025“…<p>Percentage of <i>Ae. aegypti</i> and <i>Ae. albopictus</i> trapped in each pagoda (pagodas are ordered by a decreasing percentage of <i>Ae. aegypti</i>).…”
-
3
-
4
PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis
Published 2016“…No patient discontinued patiromer because of adverse events (AEs); none had serious AEs. <b><i>Conclusions:</i></b> In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.…”
-
5
Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates.
Published 2019“…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”
-
6
-
7
-
8
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20